Summit Therapeutics Inc. (SMMT) Earnings History
Net Loss23 years of earnings data (2003–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Summit Therapeutics Inc. (SMMT) Earnings Overview
As of June 28, 2026, Summit Therapeutics Inc. (SMMT) reported trailing twelve-month net income of -$1.05B, reflecting -476.0% year-over-year growth. The company earned $-1.36 per diluted share over the past four quarters.
Looking at the long-term picture, SMMT's historical earnings data spans multiple years. The company achieved its highest annual net income of $11M in fiscal 2018.
Summit Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), RVMD (-$1.37B net income), TNGX (-$107M net income, -162.9% margin), SMMT has comparable earnings metrics. Compare SMMT vs KYMR →
SMMT Earnings vs Peers
Earnings metrics vs comparable public companies
SMMT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$1.08B | -510.7% | -$1.09B | $-1.44 | - | - |
| 2024 | -$177M | +63.4% | -$181M | $-0.25 | - | - |
| 2023 | -$482M | -640.2% | -$478M | $-0.78 | - | - |
| 2022 | -$65M | +0.5% | -$60M | $-0.34 | -11174.8% | -10225.4% |
| 2021 | -$66M | -70.0% | -$64M | $-0.71 | -4897.8% | -4764.3% |
| 2020 | -$39M | -60.7% | -$39M | $-0.56 | -6127.6% | -6185.2% |
| 2019 | -$24M | -320.7% | -$23M | $-0.73 | -3920.2% | -3697.6% |
| 2018 | $11M | +153.9% | $5M | $0.11 | 19.0% | 9.4% |
| 2017 | -$20M | +5.7% | -$26M | $-0.31 | -142.3% | -182.3% |
| 2016 | -$21M | -6.1% | -$25M | $-0.35 | -899.5% | -1046.0% |
| 2015 | -$20M | -76.9% | -$20M | $-0.34 | -1572.0% | -1588.3% |
| 2014 | -$11M | -86.8% | -$12M | $-0.29 | -603.0% | -647.9% |
| 2013 | -$6M | -44.2% | -$7M | $-0.30 | -330.4% | -363.8% |
| 2012 | -$4M | -148.0% | -$5M | $-0.27 | -223.0% | -241.5% |
| 2011 | -$2M | +77.0% | -$2M | $-0.19 | -152.6% | -170.1% |
| 2010 | -$7M | -38.9% | -$9M | $-0.19 | -614.9% | -777.4% |
| 2009 | -$5M | +83.5% | -$9M | $-0.13 | -1769.2% | -3047.6% |
| 2008 | -$32M | -60.4% | -$19M | $-0.60 | -12109.6% | -7198.9% |
| 2007 | -$20M | -239.8% | -$23M | $-0.42 | -334.1% | -388.5% |
| 2006 | -$6M | -212.4% | -$9M | $-0.16 | -292.1% | -423.8% |
| 2005 | -$2M | -2089.1% | -$3M | $-0.06 | -200.0% | -339.0% |
| 2004 | $-86,611 | -106.4% | $-537,000 | $-0.00 | -40.7% | -252.4% |
| 2003 | $-41,963 | - | $-43,787 | $-0.00 | -2300.6% | -2400.6% |
Download Data
Export SMMT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SMMT — Frequently Asked Questions
Quick answers to the most common questions about buying SMMT stock.
What is SMMT earnings per share (EPS)?
SMMT trailing twelve-month (TTM) diluted EPS is $-1.36, reflecting -476.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is Summit Therapeutics Inc.'s net income?
Summit Therapeutics Inc. (SMMT) trailing twelve-month net income is $-1.1B as of 2025. Earnings declined -476.0% year-over-year.
Is SMMT profitable?
SMMT is not currently profitable on a TTM basis, reporting a net loss of $-1.1B. Net margin is N/A. Investors should monitor for a return to profitability.
What is SMMT's earnings growth rate?
SMMT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are SMMT's profit margins?
Summit Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -270.0%.
Is SMMT growing earnings?
SMMT earnings are declining — EPS fell -476.0% year-over-year. TTM net income dropped to $-1.1B. This contrasts with the 5-year CAGR of N/A.
What was SMMT's best earnings year?
Summit Therapeutics Inc.'s highest annual net income on record is $11M, achieved in fiscal year 2018. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were SMMT's earnings last quarter?
SMMT's most recent reported quarter was Q1 2026. Net income was $-189M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.